跳转至内容
Merck

GF35079554

foil, not light tested, 50x50mm, thickness 0.025mm, as rolled, 99%

别名:

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
La
CAS号:
分子量:
138.91
MDL號碼:
分類程式碼代碼:
12141607
PubChem物質ID:
NACRES:
NA.23

化驗

99%

形狀

foil

製造商/商標名

Goodfellow 350-795-54

電阻係數

54 μΩ-cm

尺寸 × 厚度

50x50 mm × 0.025 mm

bp

3464 °C (lit.)

mp

920 °C (lit.)

密度

6.19 g/mL at 25 °C (lit.)

SMILES 字串

[La]

InChI

1S/La

InChI 密鑰

FZLIPJUXYLNCLC-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

For updated SDS information please visit www.goodfellow.com.

法律資訊

Product of Goodfellow

儲存類別代碼

4.3 - Hazardous materials which set free flammable gases upon contact with water

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Tilman B Drüeke
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
M Cozzolino et al.
The International journal of artificial organs, 30(4), 293-300 (2007-05-24)
Phosphate overload is a dramatic consequence in end-stage renal disease (ESRD) patients. Recent studies have well documented that abnormalities in mineral and bone metabolism in these patients are associated with increased cardiovascular morbidity and mortality. Elevated serum phosphate and calcium-phosphate
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门